Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Cutaneous squamous cell carcinoma, drawn from the whole corpus: 14 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Organ-transplant recipients: high incidence, no safe immunotherapy.
Who needs adjuvant therapy: gene-expression tests vs clinicopathologic staging.
Field cancerisation and multiple primaries in the elderly.
Access to Mohs surgery and dermatology capacity.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Financial help · Coverage by country · HTA decisions.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 19 changes by month →When this page itself was last checked or edited.
Adjuvant high-risk CSCC after surgery and radiation (C-POST)
Adjuvant high-risk CSCC after surgery and radiation
Adjuvant cemiplimab (C-POST, 2025: reduced locoregional and distant recurrence).
A milestone in how this cancer is treated.
Approved for cSCC